Peripheral capillary non-perfusion in treatment-naïve proliferative diabetic retinopathy associates with postoperative disease activity 6 months after panretinal photocoagulation.
Capillaries
/ pathology
Diabetic Retinopathy
/ diagnosis
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Laser Coagulation
/ methods
Male
Middle Aged
Oximetry
Postoperative Period
Prospective Studies
Regional Blood Flow
/ physiology
Retina
/ diagnostic imaging
Retinal Vessels
/ diagnostic imaging
Tomography, Optical Coherence
Visual Acuity
clinical trial
imaging
neovascularisation
retina
treatment lasers
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
11
03
2018
revised:
06
06
2018
accepted:
02
07
2018
pubmed:
3
8
2018
medline:
21
12
2019
entrez:
3
8
2018
Statut:
ppublish
Résumé
With the perspective to provide individualised panretinal laser photocoagulation (PRP) for proliferative diabetic retinopathy (PDR), we evaluated if retinal peripheral capillary non-perfusion (PCNP) and oximetry, as non-invasive markers of retinal metabolism and function, could predict disease activity 6 months after PRP. We performed a prospective, interventional study of patients with treatment-naïve PDR. Retinal oximetry and ultra-widefield fluorescein angiography were performed at baseline (BL) and three (3M) and 6 months (6M) after PRP by a navigated laser system. At 6M follow-up, patients were divided according to disease activity: active or inactive. We included 33 eyes, and 69.6% were men. At BL, the median age and duration of diabetes (with IQRs) were 51.6±23.4 and 20.0±15.0 years. Haemoglobin A We found the area of PCNP at all timepoints to be statistically larger in patients with active PDR 6 months after PRP treatment. Therefore, the area of PCNP, at baseline, may serve as a potential predictive marker for PDR activity after treatment.
Sections du résumé
BACKGROUND/AIMS
With the perspective to provide individualised panretinal laser photocoagulation (PRP) for proliferative diabetic retinopathy (PDR), we evaluated if retinal peripheral capillary non-perfusion (PCNP) and oximetry, as non-invasive markers of retinal metabolism and function, could predict disease activity 6 months after PRP.
METHODS
We performed a prospective, interventional study of patients with treatment-naïve PDR. Retinal oximetry and ultra-widefield fluorescein angiography were performed at baseline (BL) and three (3M) and 6 months (6M) after PRP by a navigated laser system. At 6M follow-up, patients were divided according to disease activity: active or inactive.
RESULTS
We included 33 eyes, and 69.6% were men. At BL, the median age and duration of diabetes (with IQRs) were 51.6±23.4 and 20.0±15.0 years. Haemoglobin A
CONCLUSION
We found the area of PCNP at all timepoints to be statistically larger in patients with active PDR 6 months after PRP treatment. Therefore, the area of PCNP, at baseline, may serve as a potential predictive marker for PDR activity after treatment.
Identifiants
pubmed: 30068515
pii: bjophthalmol-2018-312195
doi: 10.1136/bjophthalmol-2018-312195
pmc: PMC6582729
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
816-820Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing Interests: None declared.
Références
N Engl J Med. 2011 Oct 20;365(16):1520-6
pubmed: 22010918
Acta Ophthalmol. 2014 Feb;92(1):34-9
pubmed: 24330421
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5433-42
pubmed: 22786895
Am J Ophthalmol. 1998 Dec;126(6):791-7
pubmed: 9860002
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5278-5284
pubmed: 27723894
Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1025-30
pubmed: 19404666
Indian J Ophthalmol. 2015 Jul;63(7):575-81
pubmed: 26458474
Ophthalmologica. 1982;185(3):141-6
pubmed: 7133628
Diabetologia. 2009 Sep;52(9):1829-35
pubmed: 19593541
Ophthalmology. 2015 May;122(5):949-56
pubmed: 25704318
Am J Ophthalmol. 1976 Apr;81(4):383-96
pubmed: 944535
Ophthalmology. 1981 Jul;88(7):601-12
pubmed: 6167923
Acta Ophthalmol. 2018 Jun;96(4):405-410
pubmed: 29193789
Ophthalmic Physiol Opt. 2013 Jan;33(1):7-14
pubmed: 23252852
Ophthalmology. 2010 Jan;117(1):63-70
pubmed: 19880184
Br J Ophthalmol. 2018 Mar;102(3):383-387
pubmed: 28765148
Malar J. 2015 Sep 24;14:367
pubmed: 26403288
Invest Ophthalmol Vis Sci. 2013 Oct 29;54(10):7103-6
pubmed: 24114546
Br J Ophthalmol. 2012 Apr;96(4):560-3
pubmed: 22080478
Invest Ophthalmol Vis Sci. 2014 Aug 05;55(8):5365-9
pubmed: 25097242
Br J Ophthalmol. 2017 Jun;101(6):752-757
pubmed: 27553678
Ophthalmology. 2015 Dec;122(12):2465-72
pubmed: 26350546
Retina. 2012 Apr;32(4):785-91
pubmed: 22080911
Ophthalmology. 2009 Nov;116(11):2170-4
pubmed: 19744716
Acta Ophthalmol. 2017 Mar;95(2):119-127
pubmed: 27585711
Nat Rev Dis Primers. 2016 Mar 17;2:16012
pubmed: 27159554
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571